Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Health Uses Tecan Workstations to Automate Cancer Assay Development

NEW YORK (GenomeWeb News) - Genomic Health is using Tecan’s liquid-handling workstations to automate the developmental process for its cancer recurrence assays, Tecan said this week.
Genomic Health markets Oncotype DX, a gene expression assay that predicts the risk of recurrence of cancer and the likelihood of chemotherapy benefit in early-stage breast cancer patients.
Genomic Health’s director of process automation, Jay Snable, said the company is using the Tecan technology as part of a new project that is studying 761 genes “in an initial screen to create a gene profile for an assay to test for risk of recurrence of another cancer type.”
The company is using Tecan’s Freedom EVO 200 and Genesis platforms to automate all assay steps after RNA extraction, including RNA quantification and quality control, reverse transcription, and quantitative PCR assay assembly.
The workstations are also equipped with Tecan’s PosID barcode-scanning system, Tecan said.
Financial terms of the agreement were not released.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.